The Association Between Thyroid Differentiation Score and Survival Outcomes in Papillary Thyroid Carcinoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The Thyroid Differentiation Score (TDS) may predict survival in papillary thyroid carcinoma (PTC). Higher TDS is linked to longer progression-free survival, particularly in BRAFV600E-mutated PTC.
Area Of Science
- Oncology
- Molecular Diagnostics
- Genomics
Background
- Papillary thyroid carcinoma (PTC) differentiation is crucial for prognosis.
- The Thyroid Differentiation Score (TDS) quantifies differentiation using 16 gene mRNA levels.
- TDS has potential as a prognostic marker in PTC.
Purpose Of The Study
- To investigate the association between TDS and survival outcomes in PTC patients.
- To validate TDS as a prognostic biomarker across independent patient cohorts.
Main Methods
- Utilized two independent PTC cohorts: The Cancer Genome Atlas (TCGA) and MD Anderson Cancer Center (MDACC).
- Assessed progression-free interval (PFI) and overall survival (OS) as primary outcomes.
- Employed Kaplan-Meier and Cox proportional hazards models for survival analyses.
Main Results
- TDS correlated with tumor/nodal stage and driver mutation status in both cohorts.
- Higher TDS was associated with longer PFI in univariable analyses.
- TDS remained a significant predictor of PFI in the MDACC cohort after adjusting for stage, and notably in BRAFV600E-mutated tumors.
Conclusions
- TDS effectively quantifies differentiation status in PTC.
- TDS shows promise as a prognostic biomarker, especially for BRAFV600E-mutated PTC.
- Further validation may establish TDS in clinical decision-making for PTC patients.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...